Jagsonpal Pharmaceuticals Ratios

Jagsonpal Pharmaceuticals Ltd Ratios

The Jagsonpal Pharmaceuticals Ltd Ratios page provides a complete fundamental analysis of Jagsonpal Pharmaceuticals Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Jagsonpal Pharmaceuticals Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Jagsonpal Pharmaceuticals Ltd (NSE: JAGSNPHARM, BSE: 507789) is currently trading at ₹168.67, with a market capitalization of ₹11.3B. As a major player in the Health technology sector and Pharmaceuticals: generic industry, Jagsonpal Pharmaceuticals Ltd remains a key stock for fundamental analysis using Jagsonpal Pharmaceuticals Ltd Ratios.

Jagsonpal Pharmaceuticals Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Jagsonpal Pharmaceuticals Ltd P/E ratio currently stands at 26.26, making it one of the most tracked metrics in Jagsonpal Pharmaceuticals Ltd Ratios.

Historically, the Jagsonpal Pharmaceuticals Ltd P/E ratio has shown strong fluctuations:

• 2024: 26.26
• 2023: 33.04
• 2022: 28.42
• 2021: 43.57
• 2020: 12.22

The decline in Jagsonpal Pharmaceuticals Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Jagsonpal Pharmaceuticals Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 5.98.

Historical P/B trend:

• 2024: 5.98
• 2023: 3.95
• 2022: 4.78
• 2021: 6.19

Jagsonpal Pharmaceuticals Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Jagsonpal Pharmaceuticals Ltd P/S ratio currently stands at 5.41, an important part of Jagsonpal Pharmaceuticals Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 5.41
• 2023: 3.56
• 2022: 3.21
• 2021: 3.78

The rising Jagsonpal Pharmaceuticals Ltd P/S ratio indicates improved revenue valuation by investors.

Jagsonpal Pharmaceuticals Ltd Price to Cash Flow Ratio (P/CF)

The Jagsonpal Pharmaceuticals Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 23.06.

Historical Jagsonpal Pharmaceuticals Ltd Price to Cash Flow Ratio:

• 2024: 23.06
• 2023: 17.46
• 2022: 15.21
• 2021: 100.50
• 2020: 6.93

The rising Jagsonpal Pharmaceuticals Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Jagsonpal Pharmaceuticals Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Jagsonpal Pharmaceuticals Ltd EV currently stands at ₹13.35B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 13.35B
• 2023: 6.03B
• 2022: 6.51B
• 2021: 7.75B

Jagsonpal Pharmaceuticals Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Jagsonpal Pharmaceuticals Ltd EV/EBITDA ratio is currently 25.82, a key metric in Jagsonpal Pharmaceuticals Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 25.82
• 2023: 25.46
• 2022: 18.40
• 2021: 29.63

Higher Jagsonpal Pharmaceuticals Ltd EV/EBITDA suggests premium valuation.

Jagsonpal Pharmaceuticals Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Jagsonpal Pharmaceuticals Ltd D/E ratio is currently 0.04, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.04
• 2023: 0.05
• 2022: 0.04
• 2021: 0

Jagsonpal Pharmaceuticals Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Jagsonpal Pharmaceuticals Ltd ROE currently stands at 25.91%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 25.91
• 2023: 12.97
• 2022: 18.44
• 2021: 14.81

Jagsonpal Pharmaceuticals Ltd demonstrates strong profitability and efficient capital utilization.

Jagsonpal Pharmaceuticals Ltd Ratios Analysis Summary

The Jagsonpal Pharmaceuticals Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Jagsonpal Pharmaceuticals Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Jagsonpal Pharmaceuticals Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.